France’s Valneva (Euronext: VLA) has won US FDA approval for an accelerated dosing regimen of its Japanese encephalitis (JE) vaccine, Ixiaro.
Ixiaro is the only vaccine approved in the USA for protection against Japanese encephalitis – a rare, serious disease endemic to 24 countries in Asia and parts of the Western Pacific.
The accelerated dosing regimen means that adults aged 18 to 65 years may now receive two separate doses of the therapy seven days apart, rather than 28 days apart.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze